Anas Younes, MD

About Me

I am a medical oncologist and Chief of Memorial Sloan Kettering’s Lymphoma Service. I work with 16 world-class lymphoma experts who are devoted to caring for people with all types of Hodgkin lymphoma and non-Hodgkin lymphoma. We collaborate closely with our colleagues across MSK to provide personalized, comprehensive care for each of our patients. Our clinical trials research program is leading the way in discovering new treatment options that are improving outcomes and quality of life for people with lymphoma. These include immunotherapies, targeted therapies, and combination therapies.

I joined MSK in 2013 with two decades of experience in treating and managing people with lymphoma at MD Anderson Cancer Center in Houston. I also have an extensive background in translational scientific research, which means that I use findings in my lab to fuel the discovery of new therapies and treatment strategies. I am particularly interested in developing novel targeted therapies and linking them to biomarkers that can help match people with the most effective and least toxic medicines.

I have served as the principal investigator of numerous clinical trials in people with Hodgkin and non-Hodgkin lymphoma, including national and international multi-center studies. I have led the efforts to develop the first FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin, or Adcetris®), and most recently the approval of the first immune checkpoint inhibitor for lymphoma (nivolumab, or Opdivo®).

I have led a National Cancer Institute–funded Specialized Programs of Research Excellence in lymphoma focused on developing novel treatment strategies for Hodgkin and non-Hodgkin lymphoma, both at MD Anderson and MSK.

I am also leading a Specialized Center of Research collaborative grant funded by the Leukemia & Lymphoma Society and focused on the development of immune therapy for lymphoma. I serve on the Scientific Advisory Board of the Lymphoma Research Foundation and am a past member of the National Cancer Institute Lymphoma Steering Committee. When people with lymphoma come to MSK for their care, they can feel reassured that from the moment they walk through the door, they will have an entire team of experts committed to their care.

I actively post on social media about clinical trials, scientific publications, and medical advances. You can follow me on Twitter and like my page on Facebook to stay connected.

  • Clinical Expertise: Hodgkin and Non-Hodgkin Lymphomas; New Targeted Therapies
  • Languages Spoken: English
  • Education: MD, University of Damascus School of Medicine
  • Residencies: Pathology - Medical College of Ohio; Internal Medicine - SUNY Downstate Medical Center
  • Fellowships: Hematology/Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Internal Medicine; Medical Oncology

My Research

Microscope iconAn icon showing a microscope. View my lab Arrow rightAn icon showing an arrow pointing to the right.

See Anas Younes’ laboratory
research at Memorial Sloan Kettering.

See My Colleagues


Visit PubMed for a full listing of Anas Younes’ journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.

Clinical Trials Led by Anas Younes

Clinical Trials Co-Investigated by Anas Younes


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.